97 related articles for article (PubMed ID: 26320080)
1. Seletracetam enhances short term depression in vitro.
Yang X; Meehan AL; Rothman SM; Dubinsky JM
Epilepsy Res; 2015 Nov; 117():17-22. PubMed ID: 26320080
[TBL] [Abstract][Full Text] [Related]
2. Brivaracetam augments short-term depression and slows vesicle recycling.
Yang X; Bognar J; He T; Mohammed M; Niespodziany I; Wolff C; Esguerra M; Rothman SM; Dubinsky JM
Epilepsia; 2015 Dec; 56(12):1899-909. PubMed ID: 26515103
[TBL] [Abstract][Full Text] [Related]
3. Levetiracetam has an activity-dependent effect on inhibitory transmission.
Meehan AL; Yang X; Yuan LL; Rothman SM
Epilepsia; 2012 Mar; 53(3):469-76. PubMed ID: 22292611
[TBL] [Abstract][Full Text] [Related]
4. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission.
Yang XF; Weisenfeld A; Rothman SM
Epilepsia; 2007 Oct; 48(10):1861-9. PubMed ID: 17521346
[TBL] [Abstract][Full Text] [Related]
5. Levetiracetam accelerates the onset of supply rate depression in synaptic vesicle trafficking.
García-Pérez E; Mahfooz K; Covita J; Zandueta A; Wesseling JF
Epilepsia; 2015 Apr; 56(4):535-45. PubMed ID: 25684406
[TBL] [Abstract][Full Text] [Related]
6. Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.
Matagne A; Margineanu DG; Potschka H; Löscher W; Michel P; Kenda B; Klitgaard H
Eur J Pharmacol; 2009 Jul; 614(1-3):30-7. PubMed ID: 19383493
[TBL] [Abstract][Full Text] [Related]
7. Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro.
Martella G; Bonsi P; Sciamanna G; Platania P; Madeo G; Tassone A; Cuomo D; Pisani A
Epilepsia; 2009 Apr; 50(4):702-10. PubMed ID: 19055493
[TBL] [Abstract][Full Text] [Related]
8. A new mechanism for antiepileptic drug action: vesicular entry may mediate the effects of levetiracetam.
Meehan AL; Yang X; McAdams BD; Yuan L; Rothman SM
J Neurophysiol; 2011 Sep; 106(3):1227-39. PubMed ID: 21653714
[TBL] [Abstract][Full Text] [Related]
9. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.
Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974
[TBL] [Abstract][Full Text] [Related]
10. Levetiracetam inhibits endocytosis and augments short-term depression.
Pharmazie; 2018 Nov; 73(11):643-646. PubMed ID: 30396382
[TBL] [Abstract][Full Text] [Related]
11. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Sands ZA; Vandenplas C; Gillard M
Epilepsia; 2018 Sep; 59(9):e147-e151. PubMed ID: 30144048
[TBL] [Abstract][Full Text] [Related]
12. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.
Klitgaard H; Matagne A; Nicolas JM; Gillard M; Lamberty Y; De Ryck M; Kaminski RM; Leclercq K; Niespodziany I; Wolff C; Wood M; Hannestad J; Kervyn S; Kenda B
Epilepsia; 2016 Apr; 57(4):538-48. PubMed ID: 26920914
[TBL] [Abstract][Full Text] [Related]
13. Cortico-hippocampal hyperexcitability in synapsin I/II/III knockout mice: age-dependency and response to the antiepileptic drug levetiracetam.
Boido D; Farisello P; Cesca F; Ferrea E; Valtorta F; Benfenati F; Baldelli P
Neuroscience; 2010 Nov; 171(1):268-83. PubMed ID: 20804820
[TBL] [Abstract][Full Text] [Related]
14. Clinically relevant concentrations of ketamine mainly affect long-term potentiation rather than basal excitatory synaptic transmission and do not change paired-pulse facilitation in mouse hippocampal slices.
Ribeiro PO; Tomé AR; Silva HB; Cunha RA; Antunes LM
Brain Res; 2014 Apr; 1560():10-7. PubMed ID: 24637258
[TBL] [Abstract][Full Text] [Related]
15. Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission.
Yang XF; Rothman SM
Seizure; 2009 Nov; 18(9):615-9. PubMed ID: 19651528
[TBL] [Abstract][Full Text] [Related]
16. Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
Pollard JR
Curr Opin Investig Drugs; 2008 Jan; 9(1):101-7. PubMed ID: 18183537
[TBL] [Abstract][Full Text] [Related]
17. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.
Nicolas JM; Hannestad J; Holden D; Kervyn S; Nabulsi N; Tytgat D; Huang Y; Chanteux H; Staelens L; Matagne A; Mathy FX; Mercier J; Stockis A; Carson RE; Klitgaard H
Epilepsia; 2016 Feb; 57(2):201-9. PubMed ID: 26663401
[TBL] [Abstract][Full Text] [Related]
18. Opioid withdrawal for 4 days prevents synaptic depression induced by low dose of morphine or naloxone in rat hippocampal CA1 area in vivo.
Dong Z; Han H; Cao J; Xu L
Hippocampus; 2010 Feb; 20(2):335-43. PubMed ID: 19437411
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein.
Wood MD; Gillard M
Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162
[TBL] [Abstract][Full Text] [Related]
20. Favorable adverse effect profile of brivaracetam vs levetiracetam in a preclinical model.
Sanon NT; Gagné J; Wolf DC; Aboulamer S; Bosoi CM; Simard A; Messiet E; Desgent S; Carmant L
Epilepsy Behav; 2018 Feb; 79():117-125. PubMed ID: 29287214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
